CN109561681A - 多聚gitr结合分子及其用途 - Google Patents

多聚gitr结合分子及其用途 Download PDF

Info

Publication number
CN109561681A
CN109561681A CN201780045191.5A CN201780045191A CN109561681A CN 109561681 A CN109561681 A CN 109561681A CN 201780045191 A CN201780045191 A CN 201780045191A CN 109561681 A CN109561681 A CN 109561681A
Authority
CN
China
Prior art keywords
seq
binding molecule
gitr
binding
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780045191.5A
Other languages
English (en)
Chinese (zh)
Inventor
B·T-Y·王
B·A·基特
R·巴利加
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IGM Biosciences Inc
Original Assignee
IGM Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IGM Biosciences Inc filed Critical IGM Biosciences Inc
Publication of CN109561681A publication Critical patent/CN109561681A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780045191.5A 2016-07-20 2017-07-20 多聚gitr结合分子及其用途 Pending CN109561681A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364762P 2016-07-20 2016-07-20
US62/364,762 2016-07-20
PCT/US2017/043166 WO2018017889A1 (en) 2016-07-20 2017-07-20 Multimeric gitr binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
CN109561681A true CN109561681A (zh) 2019-04-02

Family

ID=60992910

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780045191.5A Pending CN109561681A (zh) 2016-07-20 2017-07-20 多聚gitr结合分子及其用途

Country Status (9)

Country Link
US (2) US20190330360A1 (enExample)
EP (1) EP3487299A4 (enExample)
JP (1) JP2019528683A (enExample)
CN (1) CN109561681A (enExample)
AU (1) AU2017300647A1 (enExample)
CA (1) CA3030659A1 (enExample)
IL (1) IL263800A (enExample)
MX (1) MX2019000799A (enExample)
WO (1) WO2018017889A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3041862B1 (en) 2013-09-05 2020-05-06 IGM Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent ig-m antibodies
WO2015120474A1 (en) 2014-02-10 2015-08-13 Igm Biosciences, Inc. Iga multi-specific binding molecules
CA2944647C (en) 2014-04-03 2025-07-08 Igm Biosciences Inc MODIFIED J STRING
US10689449B2 (en) 2015-01-20 2020-06-23 Igm Biosciences, Inc. Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
IL297997A (en) 2015-03-04 2023-01-01 Igm Biosciences Inc Cd20 binding molecules and uses thereof
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
CA2983034A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
HUE069387T2 (hu) 2015-09-30 2025-03-28 Igm Biosciences Inc Módosított J-lánccal rendelkezõ kötõmolekulák
WO2017196867A1 (en) 2016-05-09 2017-11-16 Igm Biosciences, Inc. Anti-pd-l1 antibodies
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
CN111787951B (zh) 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
CA3113268A1 (en) * 2018-10-23 2020-04-30 Igm Biosciences, Inc. Multivalent igm- and iga-fc-based binding molecules
EP4013792A4 (en) 2019-08-15 2023-10-04 IGM Biosciences Inc. IMMUNO-STIMULATING MULTIMER BINDING MOLECULES
IL297029A (en) 2020-04-22 2022-12-01 Igm Biosciences Inc Multimeric binding compounds as pd-1 agonists
US20240002526A1 (en) * 2020-11-17 2024-01-04 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies
CN113151186B (zh) * 2021-02-04 2022-02-18 上海交通大学 抗人cd271的单克隆抗体及用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010003118A1 (en) * 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Tgf-b antagonist multi-target binding proteins
CN102083966A (zh) * 2008-06-30 2011-06-01 港大科桥有限公司 大规模诱导和扩增治疗性同种异体抗原-特异性的人调节性t细胞的方法
CN103974977A (zh) * 2011-09-26 2014-08-06 Jn生物科学有限责任公司 杂交恒定区
US20150064204A1 (en) * 2013-08-30 2015-03-05 Amgen Inc. Gitr antigen binding proteins
CN108064242A (zh) * 2014-05-28 2018-05-22 阿吉纳斯公司 抗gitr抗体和其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003493A1 (en) * 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US9382319B2 (en) * 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
DK3151921T3 (da) * 2014-06-06 2019-12-02 Bristol Myers Squibb Co Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf
US10689449B2 (en) * 2015-01-20 2020-06-23 Igm Biosciences, Inc. Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
US11639389B2 (en) * 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102083966A (zh) * 2008-06-30 2011-06-01 港大科桥有限公司 大规模诱导和扩增治疗性同种异体抗原-特异性的人调节性t细胞的方法
WO2010003118A1 (en) * 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Tgf-b antagonist multi-target binding proteins
CN103974977A (zh) * 2011-09-26 2014-08-06 Jn生物科学有限责任公司 杂交恒定区
US20150064204A1 (en) * 2013-08-30 2015-03-05 Amgen Inc. Gitr antigen binding proteins
CN108064242A (zh) * 2014-05-28 2018-05-22 阿吉纳斯公司 抗gitr抗体和其使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ISABEL T VOGEL;STEFAAN W VAN GOOL;JAN L CEUPPENS;: "CD28/CTLA-4/B7 and CD40/CD40L costimulation and activation of regulatory T cells" *

Also Published As

Publication number Publication date
WO2018017889A1 (en) 2018-01-25
US20220177595A1 (en) 2022-06-09
MX2019000799A (es) 2019-06-03
US20190330360A1 (en) 2019-10-31
EP3487299A1 (en) 2019-05-29
IL263800A (en) 2019-02-28
EP3487299A4 (en) 2020-03-11
AU2017300647A1 (en) 2019-02-07
JP2019528683A (ja) 2019-10-17
CA3030659A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
CN109561681A (zh) 多聚gitr结合分子及其用途
US20230203173A1 (en) Tumor necrosis factor (tnf) superfamily receptor igm antibodies and uses thereof
CN109562165A (zh) 多聚ox40结合分子及其用途
US20210388098A1 (en) Multimeric cd137/4-1bb binding molecules and uses thereof
WO2020163646A1 (en) Anti-gitr antigen-binding domains and uses thereof
HK40043005A (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HK1242348A1 (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HK1242348B (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190402

WD01 Invention patent application deemed withdrawn after publication